MetaCap

Crescent Biopharma (CBIO) vs Wave Life Sciences (WVE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Crescent Biopharma (CBIO) has outperformed Wave Life Sciences (WVE) over the past year, losing 0.5% versus a loss of 63.7%. Over five years, WVE leads with a -35.8% price change compared with -92.7% for CBIO. Crescent Biopharma is the larger company by market cap ($543.2 million vs $504.9 million), about 1.1 times the size.

Wave Life Sciences converts more of its revenue into profit, with a net margin of -478.3% versus -1419.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CBIO-0.46%WVE-63.69%
+216%+69%-77%
Nov 21, 20251 yearNov 20, 2026
CBIO-93.09%WVE-40.60%
+333%+109%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CBIO versus WVE key metrics
MetricCBIOWVE
Share price$13.00$2.56
Market cap$543.21M$504.91M
1-day change+0.70%-5.88%
YTD return+9.61%-84.94%
1-year return-0.46%-63.69%
5-year return-92.74%-35.84%
EPS (TTM)$-7.29$-1.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$10.84M$42.73M
Revenue growth (YoY)—-60.55%
Net income (latest FY)$-153.94M$-204.38M
Operating margin-1407.52%-504.09%
Net margin-1419.61%-478.33%
52-week high$27.41$21.73
52-week low$8.72$2.55
Distance from 52-week high-52.57%-88.22%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+148.69%+549.61%
Average volume361.17K3.11M
Shares outstanding38.90M197.23M
Employees80317
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CBIO has outperformed WVE by 63.2 percentage points over the past year.
  • Wave Life Sciences is more profitable, keeping -478.3 cents of every revenue dollar as net income versus -1419.6 cents for Crescent Biopharma.

About Crescent Biopharma

CBIO stock →

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About Wave Life Sciences

WVE stock →

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees

CBIO vs WVE FAQ

Which is bigger, Crescent Biopharma or Wave Life Sciences?

Crescent Biopharma (CBIO) is larger, with a market capitalization of $543.21M compared with $504.91M for Wave Life Sciences (WVE).

Which stock has performed better over the past year, CBIO or WVE?

CBIO returned -0.46% over the past 12 months, compared with -63.69% for WVE (price return, excluding dividends). Past performance does not predict future results.

Are Crescent Biopharma and Wave Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons